Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 32: 1767-1769, 1986;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Helsingius, P.
Right arrow Articles by Lovgren, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Helsingius, P.
Right arrow Articles by Lovgren, T.

Clinical Chemistry, Vol 32, 1767-1769, Copyright © 1986 by American Association for Clinical Chemistry

Solid-phase immunoassay of digoxin by measuring time-resolved fluorescence

P Helsingius, I Hemmila and T Lovgren

We describe a time-resolved fluoroimmunoassay for the cardiac glycoside digoxin. The assay depends on the competitive distribution of Eu3+- labeled anti-digoxin antibodies between solid-phase-bound digoxin and the digoxin in the sample or standard. After this immunoreaction, the bound fraction of the Eu3+-label is dissociated from the solid phase, converted into a highly fluorescent beta-diketone chelate, and measured in a fluorometer with time-resolution (1230 Arcus, LKB-Wallac). Sample volume is 20 microL, the incubation lasts 30 min, and the concentration range of the assay for digoxin is from 0.25 to 4.0 ng/mL (0.32-5.1 nmol of digoxin per liter). Correlation with an in-house RIA was good (r = 0.97, n = 43). The sensitivity was equivalent to that of most RIAs: 0.2 ng/mL (0.25 nmol/L).


The following articles in journals at HighWire Press have cited this article:


Home page
 HypertensionHome page
A. Y. Bagrov, O. V. Fedorova, J. L. Austin-Lane, R. I. Dmitrieva, and D. E. Anderson
Endogenous Marinobufagenin-like Immunoreactive Factor and Na+,K+ ATPase Inhibition During Voluntary Hypoventilation
Hypertension, November 1, 1995; 26(5): 781 - 788.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by the American Association for Clinical Chemistry.